DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c12125) has announced the addition of Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail to their offering.
Roche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003. This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to combine strong sales and marketing with an innovative R&D policy.
Scope
--The oncology franchises of Bristol-Myers Squibb (BMS), AstraZeneca, Pfizer, Sanofi-Aventis and the Roche-Genentech partnership are examined
--Forecasts of future sales growth along with identification of potential blockbuster drugs and future market leaders
--Examination of the current oncology market and future directions in the search for innovative and profitable oncology products
Highlights
--The global oncology market continues to be dominated by Roche, whose growth was driven primarily by healthy sales of MabThera/Rituxan (rituximab), which saw sales rise 20.9% in 2003 to $2,063m. It is predicted that Roche will continue to dominate the oncology sector over the forecast period of 2003-10.
--BMS is experiencing problems. Its main oncology product, Erbitux (cetuximab), while expected to show healthy growth from 2003-10, is the only major product in its marketed portfolio. Revenue growth from 2003-10 is expected to come mainly from its subsidiary Oncology Therapeutic Network (OTN).
--AstraZenecas oncology portfolio has taken a serious hit due to negative outcome of the ISEL trial (Iressa Survival Evaluation in Lung Cancer). The results, released on December 17, 2004, indicate that Iressa (gefitinib) does not significantly prolong survival in patients with non-small cell lung cancer (NSCLC).
Reasons to Purchase
--Understand the current oncology market and who the market leaders are
--Identify where future growth for the sector is predicted to come from, and who the market leaders are predicted to be by 2010
--Identify and understand trends within the oncology sector to facilitate strategic development
CHAPTER 1 EXECUTIVE SUMMARY 6
Introduction 6
Scope and coverage of the Brief 6
Oncology portfolios key findings 9
CHAPTER 2 LEADING ONCOLOGY PLAYERS 10
CHAPTER 3 BMS: CAN THE COMPANY SUSTAIN AN ONCOLOGY PRESENCE? 15
Oncology franchise: marketed products 15
Erbitux: the survival chord between an outdated franchise and the next era? 17
Oncology franchise: pipeline analysis 21
Ixabepilone (BMS-247550) 22
The future 23
CHAPTER 4 ASTRAZENECA: CAN IT SUCCESSFULLY REPOSITION? 25
Oncology franchise: marketed products 25
Iressa: AstraZeneca's great hope falls from grace 28
Oncology franchise: pipeline analysis 30
The future 31
CHAPTER 5 PFIZER: THE 'ACQUIRE-A-FRANCHISE' MODEL 34
Oncology franchise: marketed products 34
Camptosar and Ellence: cytotoxic experience in two very different markets 35
R&D compounds 39
SU11248 40
J-107088 (endotecarin) 41
The future 41
CHAPTER 6 SANOFI-AVENTIS: PLAYING CATCH-UP TO SURVIVE? 44
Oncology franchise 44
Marketed products 44
Taxotere (docetaxel) 45
Current market position 46
Future sales growth 46
Campto (irinotecan) 47
Eloxatin (oxaliplatin) 47
Market position 48
Future sales 48
Eligard/Leuprogel (leuprolide acetate subcutaneous depot injection) 49
Fasturtec/Elitek (rasburicase) 50
R&D compounds 51
Tirazone (tirapazamine) 52
Future sales 52
Gastrimmune/G17DT 52
Future sales 53
The future 53
CHAPTER 7 THE ROCHE-GENENTECH PARTNERSHIP: THE MOST SUCCESSFUL PARTNERSHIP IN HISTORY? 55
On the origin of the species: the Roche-Genentech partnership 56
Strength and weaknesses of the partnership for Genentech 56
Strength and weaknesses of the partneship for Roche 56
Oncology franchise 57
Marketed products: Roche and Genentech 57
MabThera/Rituxan (rituximab) 59
Market position 59
Future sales 60
Herceptin (trastuzumab) 61
Avastin/anti-VEGF 63
Roche-Genentech's R&D compounds 65
Tarceva/R1415/OSI-774 66
Future partnership of Roche-Genentech: overall view 67
CHAPTER 8 APPENDIX 69
For more information visit http://www.researchandmarkets.com/reports/c12125
COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group
Contact
Home
A
Oxytetracycline